


Akums launches high-strength paracetamol oral suspension for adult and elderly care in India

22 July 2025 | News

A significant addition to the analgesic and antipyretic category



Akums Drugs & Pharmaceuticals has announced the launch of Paracetamol Oral Suspension 500mg/5ml in the Indian market. This high-strength, easy-to-administer formulation is designed to improve pain and fever management in adult and geriatric patients.

This novel oral suspension marks a significant addition to the analgesic and antipyretic category by offering therapeutic adult dosing in a minimal volume. It addresses the growing demand in India for liquid formulations suitable for patients who have difficulty swallowing tablets.

With this launch, Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats, providing a patient-friendly alternative that promotes better treatment adherence.

Paracetamol 500mg/5ml is among the most concentrated liquid paracetamol formulations available in the Indian market. By delivering an effective adult dose in just 5ml, it significantly reduces dosing frequency and volume, particularly beneficial in outpatient, hospital, and home care settings across India. It enables rapid symptom relief, especially in cases where IV access is unavailable or oral tablets are ineffective or cause discomfort.

Designed for real-world convenience, this oral suspension supports better compliance, especially in elderly patients, post-surgical recovery cases, and those with dysphagia or swallowing difficulties. Compared to traditional 250mg/5ml suspensions available in the market, which require 10–20ml per dose, the new formulation minimises confusion and enhances caregiver ease with a straightforward “5ml = 500mg” format—especially helpful in homecare and community health scenarios commonly seen in the Indian market.